Hard of hearing; Left arm pain; The initial case was missing the following minimum criteria: Invalid as ICH-unspecified AE. Upon receipt of follow-up information on 26May2021, this case now contains all required information to be considered valid.  This is a spontaneous report from a contactable consumer (patient). A 77-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on 27Jan2021 (Batch/Lot Number: EL9262, age at vaccination: 77-year-old) as single dose and second dose via an unspecified route of administration on 20Feb2021 (Batch/Lot Number: EN6200, age at vaccination: 77-year-old) as, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unknown date, the patient experienced hard of hearing, left arm pain. The patient told that his wife was on the phone due to being hard of hearing. The patient reported that he had received two doses of the Pfizer Covid-19 vaccine and after 2 1/2 weeks on 11Mar2021, the patient had blood extracted as part of his annual physical examination. The patient also requested an antibody test as part of the blood work to be done for his physical which was performed by a lab. The antibody test came back negative. the patient was concerned that for whatever reason, the patient was not protected from COVID-19. The patient read an article that, antibody tests were conducted after administering Pfizer with robust results. The patient wanted to know which antibody test to request, so the patient was provided with a regulatory authority's phone number. The test the patient had was to determine if the patient had a previous disease, recent or prior infection. But the patient wanted to find out what test the patient should have had to find out if the vaccine gave him antibodies or not. Stated that the patient did not know if there was miscommunication or if the lab did not do it right but from his reading it was the correct one. The patient wanted to know if antibodies that body developed after having COVID different from antibodies body develops after one was administered the vaccine. The patient received survey that implied there was a problem and that was not correct. Stated that the patient had no problems only left arm pain which was not previously reported. And it had nothing to do with him having arm pain. The patient sent an email questioning the results of antibody test and if the patient should get a different antibody test. The patient was calling together with his wife and would like to know how many participants were in the trial and when did the trial started. Response was provided that the population in the primary efficacy analysis included all participants 12 years of age and older who had been enrolled from 27Jul2020, and followed for the development of COVID-19 through 14Nov2020. Participants 18 through 55 years of age and 56 years of age and older began enrollment from 27July2020, 16 through 17 years of age began enrollment from 16Sept 2020, and 12 through 15 years of age began enrollment from 15Oct2020. The patient had a friend who sent her an article in regards immunocompromised patient having lower response to the vaccine. And would like to confirm this and also like to know if immunocompromised patients were actually assessed on the efficacy. And patient's neighbour across the street who were an other ethnicity mentioned that they were happy to get MODERNA CODI19 vaccine as studies showed that they are more effective for patients who are an other ethnicity in origin, so would like to know if Moderna was better than Pfizer in terms of vaccine efficacy for an other ethnicity. The patient underwent lab tests and procedures which included antibody test: negative on 11Mar2021. The outcome of events was unknown.  Follow-up attempts are completed. No further information is expected.